-
Gadolinium-Containing Contrast Agents Omniscan And Magnevist Being Recalled In The United Kingdom In February 2018
In Comparison, This December 2017 Regulatory Action By FDA In The US: “new class warning… for all gadolinium-based contrast agents” (Posted by Tom Lamb at DrugInjuryWatch.com) There seems to be a consensus…
-
FDA Recommends A Recall For Limbrel “Medical Food” Product But Primus Pharmaceuticals Is Not Complying
Reports Of Drug-Induced Liver Injury And Hypersensitivity Pneumonitis Are At Center Of This Unusual Drug Safety Controversy (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: Primus Pharmaceuticals Inc. Finally Removes Its Osteoarthritis Capsule Limbrel…
-
Jardiance – Amputations Drug Safety Issue Remains Uncertain Due To Admitted “inherent limitations of… post hoc analyses”
Jardiance Seemingly Not Associated With Amputations Per Reexamination Of Drug Company Funded EMPA-REG OUTCOME® Trial Data (Posted by Tom Lamb at DrugInjuryWatch.com) In April 2016 the European Medicines Agency (EMA) warned that…
-
New Heart Failure Drug Entresto Apparently Has Safety Signal For Hypotension (Low Blood Pressure) Side Effect
Will Recent ISMP QuarterWatch Report Prompt FDA Regulatory Action, Including Possible Drug Label Change By Novartis? (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA approved Entresto™ (sacubitril and valsartan) tablets in July…
-
Medical Researchers Continue To Study Bladder Cancer As A Possible Side Effect Of Jardiance
New Analysis Finds Significant Increased Risk Of Bladder Cancer For SGLT2 Inhibitors With Empagliflozin (Posted by Tom Lamb at DrugInjuryWatch.com) For years there has been a lingering concern over whether Sodium-Glucose Co-Transporter-2…
